{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:22:23Z","timestamp":1792030943523,"version":"4.4.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Seltorexant, a selective orexin-2 receptor (OX2R) antagonist, has demonstrated antidepressant effects in major depressive disorder (MDD), particularly among patients with higher baseline insomnia symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate flexibly dosed seltorexant vs flexibly dosed quetiapine extended release (quetiapine-XR) as adjunctive treatment to a selective serotonin (SSRI) or serotonin-norepinephrine (SNRI) reuptake inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Outpatient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Randomized, active-controlled, multicenter, exploratory phase 2 study with screening (\u22644\u00a0weeks), double-blind treatment (24\u00a0weeks), and post-treatment follow-up (2\u00a0weeks) phases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients with MDD and inadequate response to 1-3 SSRIs\/SNRIs, including an ongoing SSRI\/SNRI, in the current depressive episode.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Flexibly dosed seltorexant (20 or 40\u00a0mg) or quetiapine-XR (150 or 300\u00a0mg, with 2-day initial dosing of 50\u00a0mg) once daily as adjunctive therapy to an SSRI\/SNRI. Randomization (1:1) was stratified by baseline Insomnia Severity Index total score (\u226515 vs &amp;lt;15). Safety, tolerability, and preliminary efficacy were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcomes and measures<\/jats:title>\n                    <jats:p>Primary efficacy endpoint was time to all-cause study drug discontinuation. Secondary efficacy endpoints included change in Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score. Subgroup analyses included MADRS change by mode dose (MD; most frequent daily dose received by a patient during the study). Safety and tolerability also were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Time to all-cause discontinuation (estimated 25th percentile [80% CI]: seltorexant, 62 [38, 83] days vs quetiapine-XR, 42 [35, 61] days; hazard ratio [80% CI]: 0.83 [0.6, 1.2]) and all-cause discontinuation (seltorexant, 41.2% vs quetiapine-XR, 47.1%; 2-sided P\u2009=\u2009.5355) did not differ significantly between treatment groups. For the seltorexant 20-mg MD group, MADRS total scores consistently improved over time and reductions were numerically greater at weeks 18 and 24 versus the seltorexant 40-mg MD and the combined quetiapine-XR groups, and patients with higher baseline insomnia symptoms had greater improvement in MADRS total score, consistent with prior studies showing efficacy at 20 but not 40\u00a0mg. Treatment-emergent adverse event rates were 65.4% for seltorexant and 80.8% for quetiapine-XR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>Results support the favorable tolerability and preliminary efficacy of seltorexant 20\u00a0mg daily as adjunctive treatment in patients with MDD, especially those with insomnia symptoms, and suggest potential approaches to differentiate seltorexant from quetiapine-XR in future adequately powered studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov \u00a0identifier: NCT03321526.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyag009","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:47:43Z","timestamp":1772714863000},"source":"Crossref","is-referenced-by-count":3,"title":["Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7362-1828","authenticated-orcid":false,"given":"Christine","family":"Pinter","sequence":"first","affiliation":[{"name":"Neuroscience Clinical Development, Johnson & Johnson , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Thase","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["United States"]},{"name":"Mood & Anxiety Disorders Section, Corporal Michael J. Crescenz Veterans Affairs Medical Center , Philadelphia, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Toronto , Toronto, ON ,","place":["Canada"]},{"name":"Department of Pharmacology and Toxicology, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Statistics & Decision Sciences, Johnson & Johnson , Spring House, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Statistics & Decision Sciences, Johnson & Johnson , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gahan","family":"Pandina","sequence":"additional","affiliation":[{"name":"Neuroscience Clinical Development, Johnson & Johnson , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8868-3704","authenticated-orcid":false,"given":"Adam","family":"Savitz","sequence":"additional","affiliation":[{"name":"Neuroscience Clinical Development, Johnson & Johnson , Titusville, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne C","family":"Drevets","sequence":"additional","affiliation":[{"name":"Neuroscience Clinical Development, Johnson & Johnson , San Diego, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026041223121738600_ref1","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1017\/S1092852925000094","article-title":"Current progress in targeted pharmacotherapy to treat symptoms of major depressive disorder: moving from broad-spectrum treatments to precision psychiatry","volume":"30","author":"Singh","year":"2025","journal-title":"CNS Spectr"},{"key":"2026041223121738600_ref2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am J Psychiatry"},{"key":"2026041223121738600_ref3","doi-asserted-by":"publisher","first-page":"e051918","DOI":"10.1136\/bmjopen-2021-051918","article-title":"Quality of clinical practice guidelines for inadequate response to first-line treatment for depression according to AGREE II checklist and comparison of recommendations: a systematic review","volume":"12","author":"Gabriel","year":"2022","journal-title":"BMJ Open"},{"key":"2026041223121738600_ref4","volume-title":"Article 6(13) Referal. Summary of Product Characteristics, Labelling and Package Leaflet","author":"Seroquel","year":"2010"},{"key":"2026041223121738600_ref5","volume-title":"SEROQUEL XR\u00ae United States Prescribing Information","year":"2022"},{"key":"2026041223121738600_ref6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40263-012-0029-7","article-title":"Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression","volume":"27","author":"Kato","year":"2013","journal-title":"CNS Drugs"},{"key":"2026041223121738600_ref7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00213-017-4763-x","article-title":"Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naive patients with a first-episode of non-affective psychosis","volume":"235","author":"Vazquez-Bourgon","year":"2018","journal-title":"Psychopharmacology"},{"key":"2026041223121738600_ref8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/wps.21010","article-title":"Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study","volume":"21","author":"Hojlund","year":"2022","journal-title":"World Psychiatry"},{"key":"2026041223121738600_ref9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","article-title":"Psychotropic drug-related weight gain and its treatment","volume":"181","author":"McIntyre","year":"2024","journal-title":"Am J Psychiatry"},{"key":"2026041223121738600_ref10","doi-asserted-by":"publisher","first-page":"104516","DOI":"10.1016\/j.neubiorev.2021.104516","article-title":"Reviewing the role of the orexinergic system and stressors in modulating mood and reward-related behaviors","volume":"133","author":"Vaseghi","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"2026041223121738600_ref11","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/med.21959","article-title":"Targeting orexin receptors: recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders","volume":"43","author":"Bonifazi","year":"2023","journal-title":"Med Res Rev"},{"key":"2026041223121738600_ref12","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00406-025-01999-w","article-title":"A new direction for adjunctive therapy of difficult-to-treat depression: examining the role of orexin receptor antagonists","volume":"275","author":"Thase","year":"2025","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2026041223121738600_ref13","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s00213-025-06767-1","article-title":"Orexin receptors: possible therapeutic targets for psychiatric disorders","volume":"242","author":"Chaki","year":"2025","journal-title":"Psychopharmacology"},{"key":"2026041223121738600_ref14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41398-019-0553-z","article-title":"The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder","volume":"9","author":"Recourt","year":"2019","journal-title":"Transl Psychiatry"},{"key":"2026041223121738600_ref15","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/ijnp\/pyab050","article-title":"Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study","volume":"24","author":"Savitz","year":"2021","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026041223121738600_ref16","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/s41380-024-02846-5","article-title":"Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial","volume":"30","author":"Mesens","year":"2025","journal-title":"Mol Psychiatry"},{"key":"2026041223121738600_ref17","doi-asserted-by":"publisher","first-page":"S169","DOI":"10.1016\/j.biopsych.2025.02.419","article-title":"Seltorexant, adjunctive to antidepressants, in adults with major depressive disorder with insomnia symptoms: results of a double-blind, randomized, placebo-controlled study","volume":"97","author":"Thase","year":"2025","journal-title":"Biol Psychiatry"},{"key":"2026041223121738600_ref18","volume-title":"Poster presented at: Psych Congress","author":"","year":"2025"},{"key":"2026041223121738600_ref19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ijnp\/pyab078","article-title":"Selective orexin receptor antagonists as novel augmentation treatments for major depressive disorder: evidence for safety and efficacy from a phase 2b study of seltorexant","volume":"25","author":"Jha","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026041223121738600_ref20","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jamapsychiatry.2025.1999","article-title":"Efficacy and safety of seltorexant in insomnia disorder: a randomized clinical trial","volume":"82","author":"Mesens","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2026041223121738600_ref21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0269881118822258","article-title":"The selective orexin-2 receptor antagonist seltorexant improves sleep: an exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia","volume":"33","author":"Brooks","year":"2019","journal-title":"J Psychopharmacol"},{"key":"2026041223121738600_ref22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jad.2010.08.032","article-title":"A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder","volume":"127","author":"Bauer","year":"2010","journal-title":"J Affect Disord"},{"key":"2026041223121738600_ref23","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1586\/14737175.2013.846519","article-title":"Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy","volume":"13","author":"Weisler","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"2026041223121738600_ref24","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/da.20740","article-title":"Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial","volume":"27","author":"Liebowitz","year":"2010","journal-title":"Depress Anxiety"},{"key":"2026041223121738600_ref25","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","article-title":"Columbia classification algorithm of suicide assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants","volume":"164","author":"Posner","year":"2007","journal-title":"Am J Psychiatry"},{"key":"2026041223121738600_ref26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/009262300278623","article-title":"The Arizona sexual experience scale (ASEX): reliability and validity","volume":"26","author":"McGahuey","year":"2000","journal-title":"J Sex Marital Ther"},{"key":"2026041223121738600_ref27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"2026041223121738600_ref28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00213-002-1147-6","article-title":"Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression","volume":"163","author":"Bech","year":"2002","journal-title":"Psychopharmacology"},{"key":"2026041223121738600_ref29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"2026041223121738600_ref30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0168-8510(92)90004-u","article-title":"The QLDS: a scale for the measurement of quality of life in depression","volume":"22","author":"Hunt","year":"1992","journal-title":"Health Policy"},{"key":"2026041223121738600_ref31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/15402002.2012.636266","article-title":"Development of short forms from the PROMIS sleep disturbance and sleep-related impairment item banks","volume":"10","author":"Yu","year":"2011","journal-title":"Behav Sleep Med"},{"key":"2026041223121738600_ref32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40271-015-0132-1","article-title":"Patient-centered research to support the development of the symptoms of major depressive disorder scale (SMDDS): initial qualitative research","volume":"9","author":"McCarrier","year":"2016","journal-title":"Patient"},{"key":"2026041223121738600_ref33","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2019.02.010","article-title":"Symptoms of major depressive disorder scale: performance of a novel patient-reported symptom measure","volume":"22","author":"Bushnell","year":"2019","journal-title":"Value Health"},{"key":"2026041223121738600_ref34","doi-asserted-by":"publisher","DOI":"10.1037\/t27513-000","volume-title":"Symbol Digit Modalities Test (SDMT)","author":"Smith","year":"1973"},{"key":"2026041223121738600_ref35","volume-title":"Neuropsychological Assessment","author":"Lezak","year":"2004"},{"key":"2026041223121738600_ref36","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"2026041223121738600_ref37","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1007\/s11136-022-03180-5","article-title":"Comparing patient global impression of severity and patient global impression of change to evaluate test-retest reliability of depression, non-small cell lung cancer, and asthma measures","volume":"31","author":"Eremenco","year":"2022","journal-title":"Qual Life Res"},{"key":"2026041223121738600_ref38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026041223121738600_ref39","volume-title":"Neuropsychopharmacology","author":"Mesens"},{"key":"2026041223121738600_ref40","doi-asserted-by":"publisher","first-page":"119435","DOI":"10.1016\/j.jad.2025.119435","article-title":"Adverse events associated with four atypical antipsychotics used as augmentation treatment for major depressive disorder: a pharmacovigilance study based on the FAERS database","volume":"388","author":"Qi","year":"2025","journal-title":"J Affect Disord"},{"key":"2026041223121738600_ref41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2010.2","article-title":"Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies","volume":"67","author":"Luppino","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"2026041223121738600_ref42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3389\/fendo.2018.00431","article-title":"Depression and obesity: integrating the role of stress, neuroendocrine dysfunction and inflammatory pathways","volume":"9","author":"Ouakinin","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026041223121738600_ref43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41380-018-0017-5","article-title":"Depression and obesity: evidence of shared biological mechanisms","volume":"24","author":"Milaneschi","year":"2019","journal-title":"Mol Psychiatry"},{"key":"2026041223121738600_ref44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nut.2019.03.017","article-title":"Pathways linking obesity to neuropsychiatric disorders","volume":"66","author":"Martins","year":"2019","journal-title":"Nutrition"},{"key":"2026041223121738600_ref45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jad.2023.03.050","article-title":"Weight changes in adults with major depressive disorder: a systematic review and meta-analysis of prospective studies","volume":"332","author":"Trevino-Alvarez","year":"2023","journal-title":"J Affect Disord"},{"key":"2026041223121738600_ref46","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24com15322","article-title":"The co-occurrence of depression and obesity: implications for clinical practice and the discovery of targeted and precise mechanistically informed therapeutics","volume":"85","author":"McIntyre","year":"2024","journal-title":"J Clin Psychiatry"},{"key":"2026041223121738600_ref47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jsmc.2014.11.009","article-title":"Sleep disturbances in depression","volume":"10","author":"Murphy","year":"2015","journal-title":"Sleep Med Clin"},{"key":"2026041223121738600_ref48","doi-asserted-by":"publisher","first-page":"102048","DOI":"10.1016\/j.smrv.2025.102048","article-title":"Sleep alterations in major depressive disorder and insomnia disorder: a network meta-analysis of polysomnographic studies","volume":"80","author":"Leitner","year":"2025","journal-title":"Sleep Med Rev"},{"key":"2026041223121738600_ref49","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2215-0366(16)00012-2","article-title":"Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study","volume":"3","author":"Shilyansky","year":"2016","journal-title":"Lancet Psychiatry"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyag009\/67273759\/pyag009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/4\/pyag009\/67273759\/pyag009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/29\/4\/pyag009\/67273759\/pyag009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T03:12:27Z","timestamp":1776049947000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyag009\/8510804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyag009","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,9]]},"article-number":"pyag009"}}